Advertisement
Advertisement
U.S. markets open in 5 hours 18 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Madrigal Pharmaceuticals, Inc. (MDGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
76.71+3.37 (+4.60%)
At close: 04:00PM EDT
77.69 +0.98 (+1.28%)
After hours: 05:32PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close73.34
Open72.47
Bid0.00 x 900
Ask0.00 x 1400
Day's Range72.47 - 78.06
52 Week Range52.33 - 105.93
Volume181,294
Avg. Volume178,506
Market Cap1.312B
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-14.65
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est157.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MDGL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Madrigal Pharmaceuticals, Inc.
    Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results

    Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarter CONSHOHOCKEN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of recent corporate accomplishments and reports its second quarter 2022 financial results. Paul Friedman, M.D., Chief Executive Officer of Madrigal,

  • Benzinga

    Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis

    Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new details on changes in FibroScan controlled attenuation parameter and liver stiffness measurement along with magnetic resonance elastography, which serves as critical non-invasive measures of liver stiffness and fibrosis. Consistent with the previous top-line data, the most frequently reported adverse event

  • GlobeNewswire

    Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

    Late-breaking data from the double-blind portion of the noninvasive Phase 3 MAESTRO NAFLD-1 study show resmetirom to be safe and well-tolerated and to reduce liver fat, fibrosis measures on FibroScan and MRE, and liver enzymes, as well as multiple atherogenic lipidsIn NASH patients with well-compensated cirrhosis, resmetirom: was safe and well toleratedreduced liver fat, LDL-C, and other atherogenic lipidsreduced noninvasive measures of liver fibrosis and liver enzymesreduced liver volume by an

Advertisement
Advertisement